| Company Name: | Achillion Pharmaceuticals, Inc. | | Ticker Symbol: | ACHN | | | WWW Address: | www.achillion.com |
| CEO: | Michael D. Kishbauch | | No. of Employees: | 56 |
| Common Issue Type: | CS | | Business Description: | Achillion Pharmaceuticals, Inc. is a biopharmaceutical Company which focuses on the discovery, development and commercialization of innovative treatments for infectious diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 7.77 |  0.21 | 5.61 | 10.0 | 7.6 | 7.82 | 7.56 | 823358 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 750.2 | 96.6 | 0.74 | -0.64 | 0.00 | 0.0 | 0.0 | 11.36 - 5.42 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 7.77 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 750.2 | mil |
| Latest Shares Outstanding | 96.6 | mil |
| Earnings pS (EPS) | -0.64 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 46,554 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 56.5 | mil |
| Float as % of Shares Outstanding | 70.9 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 9,522.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 32,861.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -24.2 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -25.5 | % |
| Current Ratio | 14.1 | |
| Leverage Ratio (Assets/Equity) | 1.1 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 1.44 | $ |
| Cash pS | 0.41 | $ |
| Book-Value pS | 2.02 | $ |
| Tangible Book-Value pS | 2.02 | $ |
| Cash Flow pS | -0.50 | $ |
| Free Cash Flow pS | -0.51 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.85 | |
| Price/Tangible Book Ratio | 3.85 | |
| Price/Cash Flow | -15.4 | |
| Price/Free Cash Flow | -15.3 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 9.3 | 107 | 6,741 | 31,863 |
| 4 Weeks | 7.90 | 6.70 | 7.40 | 5.0 | 98 | 9,302 | 186,035 |
| 13 Weeks | 10.12 | 6.70 | 9.78 | -20.6 | 72 | 11,262 | 709,483 |
| 26 Weeks | 10.17 | 6.70 | 7.20 | 7.9 | 88 | 9,519 | 1,180,373 |
| 52 Weeks | 11.36 | 5.42 | 6.50 | 19.5 | 93 | 10,419 | 2,594,225 |
| YTD | 10.17 | 6.70 | - | -3.0 | 83 | 10,250 | 973,709 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 7.46 | 7.24 | 7.83 | 8.39 | 8.35 | 0.74 | 2.07 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 51.68 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 15.24 | NA | 164.09 |
| R&D | 11.48 | NA | 28.43 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -100.0 | -100.0 | 955.5 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.01 | -0.01 | 0.05 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 72.04 |
| Current Ratio | 7.4 |
| Quick Ratio (Acid Test) | 7.2 |
| Liquidity Ratio (Cash) | 7.16 |
| Receivables Turnover | 13.7 |
| Average Collection Period | 26 |
| Working Capital/Equity | 81.5 |
| Working Capital pS | 0.74 |
| Cash-Flow pS | -0.58 |
| Free Cash-Flow pS | -0.59 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 45.58 |
| Financial Leverage Ratio (Assets/Equity) | 1.1 |
| Debt Ratio | 11.6 |
| Total Debt/Equity (Gearing Ratio) | 0.01 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.5 |
| LT Debt/Total Liabilities | 3.7 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.09 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.20 |
| Tobin's Q Ratio | 9.20 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -14.68 |
| Enterprise Value (EV)/Free Cash Flow | -14.57 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 3.85 |
| Price/Book Ratio - LTM | 3.85 |
| Price/Cash Flow Ratio | -15.4 |
| Price/Free Cash Flow Ratio - LTM | -15.3 |
| Price/Sales Ratio | 6,358.01 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.11 |
| Tangible Book Value pS - LTM | 2.02 |
| Book Value pS - LTM | 2.02 |
| Capital Invested pS | 0.75 |
| Cash pS - LTM | 0.41 |
| Cash Flow pS - LTM | -0.50 |
| Free Cash Flow pS - LTM | -0.51 |
| Earnings pS (EPS) | -0.64 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -1,810.13 |
| Free Cash Flow Margin 5YEAR AVG | 158.11 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.04 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.04 |
| Return on Capital Invested (ROCI) | -65.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -77.5 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -57.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | -62.7 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.1 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 38 |
| Revenue per Employee | 46,554 |
| Net Income per Employee | -841,554 |
| Average Collection Period | 38 |
| Receivables Turnover | 13.7 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 164.02 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.04 |
| Fixed Assets Turnover | 0.19 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.14 |
| Revenue per $ Plant | 2.09 |
| Revenue per $ Common Equity | 0.04 |
| Revenue per $ Capital Invested | 0.04 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 418.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 847.5 |
| Research & Devlopment (R&D) as % of Revenue | 1495.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 1495.9 |
|
|  
| | |  |  | |
| |
